Pharma Companies Agree to COVID-19 Cease-Fire With Bench Trial on Hold
Paul Hastings partner Eric Dittmann says he hopes Mitsubishi Tanabe's voluntary agreement with Zydus Pharmaceuticals to extend the Hatch-Waxman automatic stay will serve as a model for others.
April 29, 2020 at 01:49 PM
3 minute read
Kumbaya moments aren't easy to come by in most pharmaceutical litigation.
But with a May bench trial postponed due to COVID-19 concerns, drug companies litigating the validity of patents on a diabetes treatment have jointly agreed to extend the Hatch-Waxman Act's automatic stay against launching a generic product.
Chief U.S. District Judge Freda Wolfson of the District of New Jersey signed off Friday on Mitsubishi Tanabe Pharma Corp. and Zydus Pharmaceuticals (USA) Inc.'s stipulation. It extends the 30-month stay, previously scheduled to expire Sept. 29, to 120 days after the conclusion of the bench trial, whenever that might be held.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250